The race for dominance in the mRNA vaccine arena has been marred by legal battles and patent disputes, casting a shadow over the seemingly noble quest for public health. While the official narrative portrays these conflicts as mere squabbles over technicalities, a deeper examination reveals a more sinister undercurrent at play. Moderna’s lawsuits against Pfizer and BioNTech, alleging patent infringement over mRNA technology, are not just about intellectual property; they are about control, profit, and a carefully orchestrated agenda.
The mainstream explanation paints Moderna as a defender of innovation, accusing Pfizer and BioNTech of copying its mRNA designs. However, the truth is far more intricate. Moderna’s development of mRNA technology predates the pandemic, hinting at a timeline that challenges the narrative of a spontaneous response to a global crisis. The roots of mRNA research stretch back to the 1990s, raising questions about the convenient timing of its application in the COVID-19 vaccines.
The pivot comes when we realize that the patent disputes are not isolated incidents but pieces of a larger puzzle. Moderna’s claims of infringement involve key discoveries in mRNA technology, highlighting the strategic importance of these patents in the biotech landscape. The battle for control over mRNA vaccines is not just about scientific credit; it’s about wielding power over a technology that could shape the future of medicine and surveillance.
Building upon this foundation, we uncover a web of conflicts and interests that reveal the true nature of this struggle. Moderna’s assertions of exclusive rights to mRNA encoding for the spike protein and Pfizer/BioNTech’s counterclaims of misappropriation speak to a deeper power play. The revocation of Moderna’s patent enforcement pledge in 2022 exposes a shift in priorities, from altruism to profit-seeking. The implications of this legal saga extend beyond the courtroom, affecting future vaccine profits and potentially altering the trajectory of public health policy.
The prosecution’s case is clear: the intent behind these patent disputes goes beyond protecting intellectual property; it aims to consolidate control over a technology with far-reaching implications. The means employed—legal battles, patent claims, and strategic maneuvers—reveal a calculated effort to shape the narrative around mRNA vaccines and secure dominance in the biotech industry. The opportunity to exploit a global crisis to advance hidden agendas is laid bare in the tangled threads of these lawsuits.
Looking ahead, the outlook is ominous. The convergence of biotech, surveillance, and finance in the hands of a select few raises concerns about the erosion of individual freedoms and the consolidation of power in the ‘Beast System.’ As we unravel the layers of these patent disputes, we glimpse a future where control over our health is intertwined with control over our very existence. The stakes are high, and the time to confront this looming threat is now.
